
IRISH JOURNAL OF **PSYCHOLOGICAL** VOL 19 NO 4 DEC 2002 NO 4 DEC 2002 ISSN 0790-9667



'The boy Cúchulainn' (1969) by Louis le Brocquy (Aubusson tapestry, 1999, 184 x 129cm) From an exhibition at the Irish Museum of Modern Art, Royal Hospital Kilmainham, Dublin 8. (The Táin Tapestries, 4 July 2002 – 26 January 2003). Donated by Brian Timmins and Vivienne Ward, 2001

A brighter outlook for prescribers of fluoxetine

The original brand? - 25% more expensive.¹ Is it time to change?





GEROZAC: (fluoxetine HCL) Abbreviated prescribing information: Presentation: Each capsule contains fluoxetine hydrochloride equivalent to 20 mg of fluoxetine. Indications: GEROZAC is indicated for the treatment of major depressive episodes. Dose: A dose of 20 mg/day is recommended and a maximum daily dose should not exceed 80 mg/day, which can be administered as single or divided dose, during or between meals. Patients with renal or liver disease: In cases of liver dysfunction or renal failure (GFR 10-50 ml/min), the dose should be reduced, e.g. to 20 mg every second day. Children: Fluoxetine capsules are not indicated for use in children and adolescents below the age of 18. Elderly: Caution is recommended when increasing the dose which should rarely exceed 40 mg and should not exceed 60 mg. Method of administration: For oral administration of Contraindications: Concurrent treatment with MAOIs (monoamine oxidase inhibitors). Cautionary use with other antidepressants. Not to be used where there is severe renal failure (GFR < 10ml/min). Unstable or Contraindications: Concurrent treatment with MAOIs (monoamine oxidase inhibitors). Cautionary use with other antidepressants. Not to be used where there is severe renal tallue (GFR < 10m//min). Unstable or uncontrolled epilepsy. Not to be used by nursing mothers. Hypersensitivity to any of the ingredients. **Precautions:** As with all antidepressants risk of suicide particularly at the beginning of treatment due to the delay between treatment and clinical improvement. Concomittant use of tryptophan. Epilepsy, electroconvulsive therapy, cardiovascular disease, recent myocardial infarction, diabetes, alcohol, hepatic and renal insufficiency, and overdose. **Side-effects:** rash and allergic reaction, psychosis and mood shift towards manic phase, serotonin syndrome, inappropriate secretion of antidiuretic hormone, anorexia, weight loss, appetite loss, nausea, vomiting, diarrhoea, dry mouth, dyspepsia, constipation, headache, restlessness, insomnia, anxiety, dizziness, visual disturbance, drowsiness, confusion, tremor, sweating, sedation. Small increases in diastolic blood pressure and tachycardia as well as bradycardia. Hyperpolactinemia with galactorrhea, hyponatremias. Rare cases of increased ALTs and exceptional cytolytic or mixed hepatitis. **Product authorisation number**: PA/405/36/1 Available only on prescription. **Date of preparation or last review:** January 2002. For full prescribing information please see the Summary of Product Characteristics. **Further information is available from:** Gerard Laboratories, 2004A Orchard Avenue, CityWest Business Campus, Naas Rd, Dublin 24. **FREEPHONE 1800 272 272.** Fax: 01 466 1912 **Reference: 1.** MIMS January 2002. **GMS REIMBURSABLE 1ST. FEBRUARY 2000**. Code No.: 26232 Editor-in-Chief: Brian Lawlor

Production Editor: Anne Henrichsen

Advertising Manager: Niamh Gleeson

Administrator: Andrea McAdam

Founding Editor: Mark Hartman

Associate Editors:

Ted Dinan (Cork), David King (Belfast)

Editorial Board: Ken Brown (Belfast), Patricia Casey (Dublin), Anthony Clare (Dublin), Stephen Cooper (Belfast), Thomas Fahy (Galway), Michael Fitzgerald (Dublin), Brian Leonard (Galway), Roy McClelland (Belfast), Aidan McGennis (Dublin), Ciaran O'Boyle (Dublin), Eadbhard O'Callaghan (Dublin), Art O'Connor (Dublin), Ethna O'Gorman (Belfast), Brian O'Shea (Wicklow), Ian Pullen (Edinburgh), David Sheehan (Tampa), Philip Snaith (Leeds), Hugh Staunton (Dublin), John Waddington (Dublin), Richard Williams (Victoria)

Statistical Editor:

Ronan Conroy (Dublin)

Submissions & correspondence to: The Editor,

Irish Journal of Psychological Medicine, 25 Adelaide Street, Dun Laoghaire, Co Dublin, Ireland.

Telephone: 00-353-1-2803967

Fax: 00-353-1-2807076

Email: psychological@medmedia.ie

Website: www.ijpm.org

Publisher

MedMedia Ltd. 25 Adelaide Street, Dun Laoghaire, Co Dublin, Ireland.

Printing: W&G Bairds Ltd

Subscriptions

Rates per volume of four issues (Mar, Jun, Sept, Dec) Price Regions: EU countries: €107, Stg65 Rest of World: €126, \$111 Incl. airmail postage internationally.

Subscription enquiries, orders

and cheques made payable to: Turpin Distribution Service Ltd Blackhorse Road, Letchworth SG6 1HN, England. Tel : +44 01462 672555 Fax: + 44 01462 480947 Email: CustServTurpin@turpinltd.com www.turpin-distribution.com

Circulation

2,200 to 54 countries. The Journal participates in the World Health Organisation project to improve distribution of scientific materials on mental health. Publication does not imply endorsement. Limited photocopying authorisation granted for a fee to Copyright Clearance Center, 27 Congress Street, Salem, MA 01970, USA, or to appropriate Reproduction Rights Organisation; isolated non-profit, academic photocopying excepted.

IRISH JOURNAL OF PSYCHOLOGICAL MEDICINE

VOL 19 NO 4 DEC 2002 ISSN 0790-9667

Editorial

105 Movement disorders: what the psychiatrist needs to know Radhakrishnan Renganathan, Tim Lynch

Original Papers

- **108 A 15 year follow-up of schizophrenia in Ireland** Aine Finnerty, Fiona Keogh, Anne O'Grady-Walsh, Dermot Walsh
- **115 Down syndrome, dementia and macrocytosis** Vee Prasher, Jay Viswanathan, Roger Holder
- **121 Dealing with violent and aggressive patients: at what cost to nurses?** Jillian Crabbe, David A Alexander, Susan Klein, Shona Walker, John Sinclair

Reviews

125 What is the profile of post-traumatic reactions within medical literature? A survey of eight journals

Alastair M Hull, Patricia M Doherty, Linda J Bowes

Historical

128 Saints-protectors from headaches – historical hints of suggestive therapy

Ante Skrobonja, Vesna Golubovic, Snjezana Golubovic, Amir Muzur, Ante Skrobonja Jr

Case reports

130 Koro – A case report in an Eastern European asylum seeker in Ireland Noel Kennedy, Michael McDonough


117a John Dunne Medal

- 120a Guidelines for Authors
- 124a Subscriptions
- 132 Letters to the Editor
- 134 Index to Keywords
- 135 Index to Authors

Indexed and abstracted by BIOLOGICAL ABSTRACTS (BIOSIS Previews); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE/INIST: PASCAL; EXCERPTA MEDICA/EMBASE; INSTITUTE FOR SCIENTIFIC INFORMATION: CURRENT CONTENTS/ Social & Behavioural Sciences (Social Science CITATION INDEX, Research Alert); PSYCHOLOGICAL ABSTRACTS (PsycINFO/PsycIIT); Cumulative Index to Nursing & Allied Health Literature, Current AIDS Literature (CAB Abstracts), International Pharmaceutical Abstracts, Linguistics & Language Behaviour Abstracts, Nutrition Abstracts and Reviews, (CAB Abstracts), Referativnyi Zhurnal, Social Planning/Policy & Development Abstracts, Social Work Research & Abstracts, Sociological Abstracts.

Microfilm, microfiche & article copies from **University Microfilms International**, 300 North Zeeb Rd., Ann Arbor, MI 48106, USA. Journal included in the **Adonis** service, whereby article copies can be printed out from compact disks (CD-ROM) on demand; explanatory leaflet available from ADONIS BV, PO Box 639, 1000 AV Amsterdam, The Netherlands. Journal listed in **Ulrich's** International Periodicals Directory **(Bowker** International Serials Database), **EBSCO's** Selected Periodicals for the Medical and Health Sciences, & EBSCO's Librarians' Handbook.

In Depression & Anxiety...



Abbreviated from a constant of the prescribing the prescribing to the prescribing to the presentation. Tables to the presentation is the presentat

monitored. Although Lustral has been shown to have no adverse interaction with alcohol, concomitant use with alcohol is not recommended. The potential for Lustral to interact with other highly protein bound drugs should be borne in mind, Interactions with e.g. warfarin, diazepam, tolbutamide and cimetidine have not been fully assessed. With warfarin prothrombin time should be monitored when Lustral is initiated or stopped. Side-Effects: Dry mouth, nause, diarthoea/loose stook, ejaculatory delay, tremor, increased sweating, dizziness, insomnia, somolence, headache, anoresia and dyspepsia. Rarely, antormal LUFS, hyponataremia. Additionally agitation and hyperkinesia in paediatric OCD patients. The following have been reported with Lustral but may have no causal relationship: vomiting, addominal pain, movement disorders, convulsions, menstrual irregularities, hyperprolactinaemia, altered platelet function, abnormal bleeding and purpura. As with other serotonin re-uptake inhibitors are reports of agitation, confusion, depersonalisation, hallucinations, nervousness, postural

hypotension, hypo/hypertension, tachycardia and arrhythmias. Withdrawal reactions have been reported with Lustral. Common symptoms include diziness, paneathesia, headache, anxiety and nausea. Abrupt discontinuation of treatment with Lustral should be avoided. The majority of symptoms experienced on withdrawal of Lustral are non-serious and self-limitign. Legal Category: S1A. Package Quantities: S0mg tablet (PA 822/1/4) Calendar pack of 28. Product LOM 2015 Calendar pack of 28. Product Authorisation Holder: Pitzer (Ireland) Limited, Parkway House, Ballymount Road Lower, Dublin 12, Republic of Ireland. Further Information on request: Pitzer (Ireland) Limited. Date last revised: February 2002

